Corporate Governance

We are proud of our history of strong corporate governance practices, and we seek to maintain the highest standards of ethics while building value for all of our stakeholders.
Board of Directors
Our board of directors consists of eight members. The board has determined that all current board members, with the exception of Jonathan W. Ayers, our Chief Executive Officer, are “independent” as defined by the rules of the NASDAQ Stock Market.
The board of directors is responsible for monitoring the company’s overall performance. Among other things, the board of directors and its committees establish corporate policies; oversee compliance and ethics; review the performance of the Chief Executive Officer and other executives; review and approve certain transactions; and review the company’s long-term strategic plans.
Jonathan W. Ayers 

Chairman, President and Chief Executive Officer
IDEXX Laboratories, Inc.
![]() | Jonathan W. AyersChairman, President and Chief Executive Officer IDEXX Laboratories, Inc. Jonathan W. Ayers, age 55, has been Chairman, President and Chief Executive Officer of IDEXX since January 2002. Prior to joining IDEXX, Mr. Ayers held various positions at United Technologies Corporation and its business unit Carrier Corporation. From 1999 to 2001, Mr. Ayers was President of Carrier Corporation, the then-largest business unit of United Technologies and the world's largest manufacturer of commercial and residential HVAC systems and equipment and the leading producer of commercial and transport refrigeration equipment. From 1997 to 1999, Mr. Ayers was President of Carrier Asia Pacific Operations, and from 1995 to 1997, Mr. Ayers was Vice President, Strategic Planning at United Technologies. In his roles at United Technologies Mr. Ayers gained significant operating experience in leading a global business unit; developed management, finance and strategic planning skills; and developed experience in acquisition integration, line and international operations, and marketing and product development. Prior to joining United Technologies, from 1986 to 1995, Mr. Ayers held various positions at Morgan Stanley & Co. in mergers and acquisitions and corporate finance. Mr. Ayers worked as a strategy consultant for Bain & Company from 1983 to 1986 and was in the field sales organization of IBM's Data Processing Division from 1978 to 1981. Mr. Ayers holds an undergraduate degree in molecular biophysics and biochemistry from Yale University and graduated from Harvard Business School in 1983. |


Partner and co-founder
Monitor Company Group, L.P.
![]() | Thomas CraigPartner and co-founder Monitor Company Group, L.P. Thomas Craig, age 57, has been a Director of IDEXX since December 1999. Mr. Craig has extensive experience in management consulting and corporate growth strategy. In 1983, Mr. Craig co-founded Monitor Company Group, L.P., a global management consulting firm committed to helping clients improve their competitiveness and providing services in strategy consulting, capability building, and capital services. Mr. Craig has broad international and industry experience. He has worked in over 70 countries on six continents and has led over 400 projects over the past 32 years, mostly for Fortune 500 companies or their international equivalents, or at the highest levels of government. Mr. Craig continues to be a partner at Monitor and is responsible for development of various emerging narkets, as well as serving clients in North America. He is active in various executive education programs and leadership development initiatives. Mr. Craig received an AB from Princeton University and holds an MBA from Harvard Business School. |


Retired Executive Chairman of the Board
Cornerstone Brands, Inc.
![]() | William T. EndRetired Executive Chairman of the Board Cornerstone Brands, Inc. William T. End, age 64, has been a Director of IDEXX since July 2000. Mr. End was Chairman and Chief Executive Officer of Cornerstone Brands, Inc., a privately-held catalog retailer, from 1995 to 2001, and Executive Chairman of that company from 2001 until his retirement in 2002. In these executive roles Mr. End was responsible for all corporate functions as well as Board function and activity. Prior to joining Cornerstone Brands, Mr. End held various positions at Land’s End, Inc. from 1991 to 1995, including President and Chief Executive Officer. From 1975 to 1991, Mr. End held various positions at L.L. Bean, Inc., a privately-held catalog retailer, including Executive Vice President and Chief Marketing Officer. Mr. End has significant executive experience with a particular focus on marketing and product development. Mr. End was a director and chairman of Eddie Bauer Holdings, Inc., a catalog retailer, from 2005 to 2010, a director of New England Business Services, Inc., a business to business direct marketing company, from 2000 to 2003, Hannaford Bros. Co., a supermarket and grocery retailer, from 1995 to 2000, and Land’s End, Inc., a catalog retailer, from 1990 to 1995. He also has been a director of several non-public companies. In these capacities, Mr. End has developed significant experience with board function and corporate governance. Mr. End received a BSBA from Boston College and earned an MBA from Harvard Business School. |


Senator John Heinz Professor of Environmental Management
Harvard Business School
![]() | Rebecca M. Henderson, PhDSenator John Heinz Professor of Environmental Management Harvard Business School Rebecca M. Henderson, age 51, has been a Director of IDEXX since July 2003. Dr. Henderson has extensive experience in corporate strategy, with a focus on high-technology business. She has worked with numerous Fortune 500 companies on growth strategies related to innovation. In July 2009 Dr. Henderson joined Harvard Business School as the Senator John Heinz Professor of Environmental Management where she specializes in strategy and organizational change. From 1998 to 2009, Dr. Henderson served as the Eastman Kodak Professor of Management at the Sloan School of the Massachusetts Institute of Technology. Dr. Henderson also has board oversight and corporate governance experience as a director since July 2009 of Amgen Inc., a publicly-traded human therapeutics company in the biotechnology industry, and as a director of several private company and non-profit organization boards. Dr. Henderson also has been a research fellow at the National Bureau of Economic Research since 1995, and sits on the editorial boards of Management Science, Research Policy, The Economics of Innovation and New Technology, and the Strategy Management Journal. Dr. Henderson holds an undergraduate degree from the Massachusetts Institute of Technology and a PhD in business economics from Harvard University. |


Former Dean, College of Engineering
Villanova University
![]() | Barry C. Johnson, PhDFormer Dean, College of Engineering Villanova University Barry C. Johnson, age 68, has been a Director of IDEXX since March 2006. Dr. Johnson has substantial experience in science and technology and in research and product development. Dr. Johnson served as Dean, College of Engineering, Villanova University, from August 2002 until his retirement in May 2006. From July 2000 to April 2002, he served as Senior Vice President and Chief Technology Officer of Honeywell International, Inc., a worldwide diversified technology and manufacturing company with sales in 2001 exceeding $23 billion. As Chief Technology Officer, Dr. Johnson was responsible for setting the strategic direction and prioritization of Honeywell’s research and development organization, which was supported by a global network of more than 15,000 engineers, scientists and researchers. Prior to Honeywell, Dr. Johnson served in several roles beginning in 1976 at Motorola, Inc., a global leader in providing integrated communications solutions, including Corporate Vice President and Chief Technology Officer for that company’s Semiconductor Product Sector. Dr. Johnson also has board oversight and corporate governance experience from his service as a director since September 2005 of Rockwell Automation, Inc., a publicly-traded global automation solutions company, and as a director since August 2003 of Cytec Industries, Inc., a publicly-traded global specialty chemicals and materials company. Dr. Johnson earned a BME (Bachelor of Mechanical Engineering) from Villanova University and holds a PhD and MS in metallurgical engineering and materials science from Carnegie-Mellon University. He also completed a three-year advanced business administration program through Arizona State University’s College of Business Administration. |


Executive Vice President and Chief Financial Officer
Iron Mountain Incorporated
![]() | Brian P. McKeonExecutive Vice President and Chief Financial Officer Iron Mountain Incorporated Brian P. McKeon, age 49, has been a Director of IDEXX since July 2003. As a CPA with nearly 20 years of experience as a finance executive, Mr. McKeon has significant background in finance, financial reporting, financial controls, mergers and acquisitions, and strategic planning, including as Executive Vice President and Chief Financial Officer for Iron Mountain Incorporated since April 2007. Iron Mountain is a publicly-traded provider of information protection and storage services worldwide with over $3 billion in revenues during 2009. Mr. McKeon was also Executive Vice President and Chief Financial Officer of The Timberland Company from March 2000 to April 2007. Timberland is a publicly-traded provider of premium outdoor footwear, apparel and accessories that had over $1.5 billion in revenues in 2006, the last full fiscal year of Mr. McKeon’s tenure. From 1991 to 2000, Mr. McKeon held several finance and strategic planning positions with PepsiCo Inc., serving most recently as Vice President, Finance at Pepsi-Cola, North America. Prior to joining PepsiCo, Mr. McKeon worked as a strategy consultant with the Alliance Consulting group and as an auditor with Coopers & Lybrand. Mr. McKeon earned a BS from the University of Connecticut and received an MBA from Harvard University. |


Retired Chairman and Chief Executive Officer
New England Business Service
![]() | Robert J. MurrayRetired Chairman and Chief Executive Officer New England Business Service Robert J. Murray, age 70, has been a Director of IDEXX since February 2005. Mr. Murray served as Chairman of the Board and Chief Executive Officer of New England Business Service, Inc., or NEBS, from 1995 until his retirement in 2004. NEBS was a publicly-traded business to business direct marketing company and had over $500 million in sales during the last fiscal year prior to Mr. Murray’s retirement. As the chief executive officer of NEBS, Mr. Murray was responsible for all aspects of the business. Mr. Murray held various executive positions at The Gillette Company from 1961 to 1995, including Executive Vice President, North Atlantic Group from 1991 to 1995, and Chairman of the Board of Management of Braun AG, a subsidiary of Gillette headquartered in Germany, from 1985 to 1990. In these positions, Mr. Murray developed substantial experience in international business operations and led all aspects of the business for these divisions. Mr. Murray has served as a director for the following public companies since the years indicated: The Hanover Insurance Group, Inc., a property and casualty insurance company (since 1996); LoJack Corporation, an automobile security system manufacturer (since 1992); Tupperware Brands Corporation, a consumer-direct seller of personal and household products (since 2004); and Delhaize Group, an international food retailer based in Belgium (since 2001). Mr. Murray’s background as a chief executive as well as a leader of a major business unit of a large multi-national corporation, and as a director of several public companies, has provided him with extensive management skills and experience in board function and corporate governance. Mr. Murray received a BS and BA from Boston College and an MBA from Northeastern University and he completed Harvard Business School’s Advanced Management Program. |


Retired Vice Chairman
Health Management Associates, Inc.
![]() | Joseph V. VumbaccoRetired Vice Chairman Health Management Associates, Inc. Joseph V. Vumbacco, age 65, has been a Director of IDEXX since February 2010. Mr. Vumbacco served as Chief Executive Officer of Health Management Associates, Inc., or HMA, from 2001 until June 2007, and as Vice Chairman of HMA from June 2007 until his retirement in December 2007. HMA is a premier operator of acute care hospitals in non-urban communities throughout the United States, and had over $4.1 billion in revenues during the last fiscal year prior to Mr. Vumbacco’s retirement. As the Chief Executive Officer of HMA, Mr. Vumbacco was responsible for all aspects of the business. Prior to becoming Chief Executive Officer, Mr. Vumbacco held several key positions at HMA from 1996, including Chief Operating Officer, Chief Administrative Officer, Executive Vice President, and President. Before joining HMA, Mr. Vumbacco had a nearly 15-year career with The Turner Corporation, a publicly-traded construction and real estate company, where he gained extensive operational and staff responsibilities, including as an Executive Vice President. Mr. Vumbacco also served as Senior Vice President and General Counsel at The F&M Schaefer Corporation, a publicly-traded brewing company, and prior to that was an attorney at the Wall Street firm of Mudge Rose Guthrie & Alexander where he specialized in corporate and securities law. Mr. Vumbacco holds an undergraduate degree from Bowdoin College, a law degree from Syracuse University College of Law, and he also completed the Finance Program for Senior Executives at the Harvard Business School. |
Board Committees
The board of directors has established audit, compensation, nominating and governance, and finance committees. Each of these committees acts pursuant to a written charter approved by the board.
Charter

The Audit Committee is a committee of the Board of Directors of IDEXX Laboratories, Inc. Its primary function is to assist the Board in fulfilling its oversight responsibilities by overseeing the accounting, internal control and financial reporting processes, the audit process of the Company and related party transactions.
The Company’s management is responsible for preparation, presentation and integrity of the Company’s financial statements; the appropriateness of the accounting principles and reporting policies that are used by the Company; establishing and maintaining disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)); establishing and maintaining the effectiveness of disclosure controls and procedures (as defined in Rule 13a-15(f) of the Exchange Act); evaluating the effectiveness of internal control over financial reporting; and evaluating any change in internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, internal control over financial reporting. The independent auditors are responsible for auditing the Company’s financial statements and for reviewing the Company’s unaudited interim financial statements as well as expressing an opinion on (i) management’s assessment of the effectiveness of internal control over financial reporting and (ii) the effectiveness of internal control over financial reporting. The authority and responsibilities set forth in this Charter do not reflect or create any duty or obligation of the Audit Committee to plan or conduct any audit, to determine or certify that the Company’s financial statements are complete, accurate, fairly presented, or in accordance with generally accepted accounting principles (“GAAP”) or applicable law, or to guarantee the independent auditor’s report.
I. Organization
The Audit Committee will consist of at least three members of the Board of Directors. Each member of the Audit Committee shall be independent as defined by NASDAQ rules, meet the criteria for independence set forth in Rule 10A 3(b)(1) under the Exchange Act (subject to the exemptions provided in Rule 10A 3(c)), and not have participated in the preparation of the financial statements of the Company or any current subsidiary of the Company at any time during the past three years. At least one member of the Audit Committee shall be an “audit committee financial expert” as defined under the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In addition, at least one member must have past employment experience in finance or accounting, requisite professional certification in accounting, or any other comparable experience or background which results in the individual’s financial sophistication, including being or having been a chief executive officer, chief financial officer or other senior officer with financial oversight responsibilities. Each member of the Audit Committee must be able to read and understand fundamental financial statements, including the Company’s balance sheet, income statement, and cash flow statement, at the time of his or her appointment to the Audit Committee. The Nominating and Governance Committee of the Board of Directors shall determine annually whether each member of the Audit Committee meets the requirements of this paragraph.
Audit Committee members and the Committee chairman shall be designated by a majority vote of the full Board of Directors upon recommendation of the Nominating and Governance Committee. The Board of Directors may remove members of the Committee from such committee, with or without cause. The Board shall elect the Chairman of the Committee. The Chairman of the Committee shall periodically report to the Board regarding the activities of the Committee.
II. Duties and Responsibilities
In meeting its responsibilities, the Audit Committee shall perform the following activities:
A. Oversight of the Independent Auditors and Audit Process:
- The Audit Committee is solely responsible for appointing, evaluating, retaining, compensating and, when necessary, terminating the engagement of the independent auditors. The Audit Committee may, in its discretion, seek stockholder ratification of the independent auditor it appoints. The Audit Committee is empowered without further action of the Board, to cause the Company to pay the compensation of the independent auditors established by the Audit Committee.
- The Audit Committee shall pre-approve all services associated with the annual audit to be provided to the Company by the independent auditor or other firms performing services on behalf of the independent auditor. The Audit Committee shall pre-approve all other services (review, attest and non-audit) to be provided to the Company by the independent auditor; provided, however, that de minimis non-audit services may instead be approved in accordance with applicable SEC rules.
- The Audit Committee shall oversee the work of the independent auditors, who shall report directly to the Audit Committee. Such oversight shall include resolution of disagreements between management and the independent auditors regarding financial reporting.
- The Audit Committee shall provide an open avenue of communication between the independent auditors and the Board of Directors.
- The Audit Committee shall take, or recommend that the full Board take, appropriate action to oversee the independence of the independent auditor. In connection with this responsibility, the Audit Committee shall obtain and review the written disclosures and the letter from the independent auditor required by applicable requirements of the Public Company Oversite Board (the "PCAOB") regarding the independent auditor's communications with the Audit Committee concerning independence. The Audit Committee shall actively engage in dialogue with the independent auditor concerning any disclosed relationships or services that might impact the objectivity and independence of the auditor.
- The Audit Committee shall conduct an annual review of the performance of the independent auditors, including a review of (1) the background and performance of partners and managers assigned to the Company’s account, (2) quality control procedures established by the independent auditors, and (3) material issues raised by the most recent internal quality-control review, or peer review, of the firm, or by any inquiry or investigation by governmental or professional authorities, and any steps taken to deal with any such issues.
- The Audit Committee shall ascertain that (1) the lead (or concurring) audit partner from any public accounting firm performing audit services serves in that capacity for no more than five fiscal years of the Company and (2) any partner other than the lead or concurring partner serves no more than seven years at the partner level on the Company’s audit.
- The Audit Committee shall set clear hiring policies for employees or former employees of the independent auditors.
- The Audit Committee shall consider and review, with management, the rationale for employing audit firms other than the principal independent auditors.
B. Oversight of Internal Auditors:
- The Audit Committee shall review the charter, plans, activities, staffing and organizational structure of the internal audit function and shall review and concur in the appointment, replacement, reassignment, or dismissal of the Director of Internal Auditing or person having similar responsibilities. The Audit Committee will provide an open channel of communication between the internal auditors and the Board.
- The Audit Committee shall consider and review with the internal auditors and management:
- the objectivity, independence and effectiveness of the internal auditors;
- the internal audit risk assessment process, audit scope and plans of the internal auditors;
- the coordination of effort with the independent auditors to assure completeness of coverage, reduction of redundant efforts, and the effective use of audit resources;
- the quality and adequacy of the Company’s internal accounting controls; and
- any significant findings and recommendations of the independent auditors and internal auditors together with management’s responses thereto.
C. Oversight of the Financial Reporting Process:
- The Audit Committee shall consider and review with management and the independent auditors prior to the filing of each periodic report:
- the Company’s financial statements and related footnotes;
- the quality of the Company’s earnings from a subjective and an objective standpoint;
- judgments of the independent auditors about the quality of the Company’s accounting principles as applied in its financial reporting for its financial statements;
- any significant events or transactions occurring during the period being reported;
- any changes in accounting estimates, policies and practices, unusual or significant commitments or liabilities, and legal and regulatory matters that may have a material impact on the financial statements;
- the reports to be filed with the SEC and other published documents containing the Company’s financial statements and consider whether the information contained in these documents is consistent with the information contained in the financial statements;
- internal control matters required to be communicated to the Committee by management, including all significant deficiencies in the design or operation of internal controls that could adversely affect the Company’s ability to record, process, summarize and report financial data, and any allegation of fraud that involves management or other employees who have a significant role in the Company’s internal controls;
- the process used by management to evaluate the effectiveness of disclosure controls and procedures and the results of management’s evaluation of such effectiveness; and
- the Company’s earnings press release.
- The Audit Committee shall consider and review with management and the independent auditors at the completion of the annual audit examination:
- Report provided by the independent auditors on the following matters:
- all critical accounting policies and practices in use;
- all alternative treatments of financial information within GAAP that have been discussed with management, ramifications of the use of such alternative treatments, and the treatment preferred by the independent auditors; and
- other material written communications between the independent auditors and management, such as any management letter or schedule of unadjusted differences.
- The independent auditors’ audit of the financial statements and report thereon, including any attestation report on management’s assessment of the internal control system.
- Report provided by the independent auditors on the following matters:
- The Audit Committee shall consider whether it will recommend to the Board that the Company’s audited financial statements be included in the Company’s Annual Report on Form 10-K.
- The Audit Committee shall review and discuss with the Company’s management and independent auditor the Company’s audited financial statements, including the matters required to be discussed by the Statement on Auditing Standards No. 61, as amended (AICPA, Professional Standards, Vol. 1. AU section 380), as adopted by the PCAOB.
D. Other Oversight Responsibilities:
- The Audit Committee shall maintain procedures for:
- the receipt, retention, and treatment of complaints regarding accounting, internal control, and auditing matters; and
- the confidential, anonymous submission by employees of concerns regarding questionable accounting or auditing matters.
- The Audit Committee shall coordinate the Board of Directors' oversight of the Company’s internal control over financial reporting and disclosure controls and procedures. The Audit Committee shall receive and review the reports of the Chief Executive Officer and Chief Financial Officer required by Rule 13a-14 of the Exchange Act.
- The Audit Committee shall annually review the adequacy of the Company’s computerized information system controls and security.
- The Audit Committee shall periodically review the Code of Ethics and review with the General Counsel and the Director of Internal Auditing the results of their monitoring of compliance with the Code of Ethics.
- The Audit Committee shall periodically meet independently and in separate executive sessions with the internal auditors, the independent auditors, and management.
- The Audit Committee shall prepare the report required by the rules of the SEC to be included in the Company’s annual proxy statement.
- The Audit Committee shall report Audit Committee actions to the Board of Directors with such recommendations, as it may deem appropriate.
- The Audit Committee is authorized to conduct or instruct management to conduct investigations into any matters within its scope of responsibilities.
- The Audit Committee shall review the Company’s policies and procedures for reviewing and approving or ratifying related party transactions (i.e., transactions within the scope of Item 404 of Regulation S-K ), including the Company’s Related Party Transaction Policy, and recommend any changes to the Board.
- The Audit Committee shall review all related party transactions (defined as transactions required to be disclosed pursuant to Item 404 of Regulation S-K) for potential conflict of interest situations on an ongoing basis, and all such transactions must be approved or ratified by the Audit Committee.
- The Audit Committee shall review with management the Company’s policies and procedures with respect to officers’ expense accounts and perquisites, including their use of corporate assets, and consider the results of any review of these areas by the internal auditor or the independent auditors.
- The Audit Committee shall discuss with management the Company’s major policies with respect to risk assessment and risk management, including insurance coverage.
- The Audit Committee will perform such other functions as assigned by law, NASDAQ regulation, the Company’s charter or by-laws, or the Board of Directors.
- The Audit Committee shall review the structure and function of the Company’s Finance organization at least annually.
- The Audit Committee shall periodically review critical accounting topics or processes of the Company as determined by the Chief Financial Officer, independent auditors or the Committee.
III. Process and Administration
- The Audit Committee shall meet as frequently as required to fulfill the requirements of its charter or as circumstances require. The Audit Committee will ask members of management or others to attend the meeting and provide pertinent information as necessary. The Audit Committee may also act by unanimous written consent in lieu of a meeting. The Audit Committee shall keep such records of its meetings as it shall deem appropriate.
- The Audit Committee may form and delegate authority to one or more subcommittees, as it deems appropriate from time to time under the circumstances (including a subcommittee consisting of a single member). Any decision of a subcommittee to pre-approve audit, attest or non-audit services shall be presented to the full Audit Committee at its next scheduled meeting.
- The Audit Committee shall review and update, if necessary, its charter at least annually and recommend any proposed changes to the Board for approval.
- The Audit Committee may retain such independent legal, accounting and other advisors as it deems necessary. Such independent advisors may be the regular advisors to the Company. The Company shall provide appropriate funding, as determined by the Audit Committee, for payment of fees of any such advisors.
- The Audit Committee is empowered, without further action by the Board, to cause the Company to pay the ordinary administrative expenses of the Audit Committee that are necessary or appropriate in carrying out its duties.

![]() | Brian P. McKeonExecutive Vice President and Chief Financial Officer Iron Mountain Incorporated Brian P. McKeon, age 49, has been a Director of IDEXX since July 2003. As a CPA with nearly 20 years of experience as a finance executive, Mr. McKeon has significant background in finance, financial reporting, financial controls, mergers and acquisitions, and strategic planning, including as Executive Vice President and Chief Financial Officer for Iron Mountain Incorporated since April 2007. Iron Mountain is a publicly-traded provider of information protection and storage services worldwide with over $3 billion in revenues during 2009. Mr. McKeon was also Executive Vice President and Chief Financial Officer of The Timberland Company from March 2000 to April 2007. Timberland is a publicly-traded provider of premium outdoor footwear, apparel and accessories that had over $1.5 billion in revenues in 2006, the last full fiscal year of Mr. McKeon’s tenure. From 1991 to 2000, Mr. McKeon held several finance and strategic planning positions with PepsiCo Inc., serving most recently as Vice President, Finance at Pepsi-Cola, North America. Prior to joining PepsiCo, Mr. McKeon worked as a strategy consultant with the Alliance Consulting group and as an auditor with Coopers & Lybrand. Mr. McKeon earned a BS from the University of Connecticut and received an MBA from Harvard University. |
Thomas CraigPartner and co-founder Monitor Company Group, L.P. Thomas Craig, age 56, has been a Director of IDEXX since December 1999. Mr. Craig has extensive experience in management consulting and corporate growth strategy. In 1983, Mr. Craig co-founded Monitor Company Group, L.P., a global management consulting firm committed to helping clients improve their competitiveness and providing services in strategy consulting, capability building, and capital services. Mr. Craig has broad international and industry experience. He has worked in over 70 countries on six continents and has led over 400 projects over the past 32 years, mostly for Fortune 500 companies or their international equivalents, or at the highest levels of government. Mr. Craig continues to be a partner at Monitor and is responsible for development of various emerging narkets, as well as serving clients in North America. He is active in various executive education programs and leadership development initiatives. Mr. Craig received an AB from Princeton University and holds an MBA from Harvard Business School. |
![]() | Barry C. Johnson, PhDFormer Dean, College of Engineering Villanova University Barry C. Johnson, age 68, has been a Director of IDEXX since March 2006. Dr. Johnson has substantial experience in science and technology and in research and product development. Dr. Johnson served as Dean, College of Engineering, Villanova University, from August 2002 until his retirement in May 2006. From July 2000 to April 2002, he served as Senior Vice President and Chief Technology Officer of Honeywell International, Inc., a worldwide diversified technology and manufacturing company with sales in 2001 exceeding $23 billion. As Chief Technology Officer, Dr. Johnson was responsible for setting the strategic direction and prioritization of Honeywell’s research and development organization, which was supported by a global network of more than 15,000 engineers, scientists and researchers. Prior to Honeywell, Dr. Johnson served in several roles beginning in 1976 at Motorola, Inc., a global leader in providing integrated communications solutions, including Corporate Vice President and Chief Technology Officer for that company’s Semiconductor Product Sector. Dr. Johnson also has board oversight and corporate governance experience from his service as a director since September 2005 of Rockwell Automation, Inc., a publicly-traded global automation solutions company, and as a director since August 2003 of Cytec Industries, Inc., a publicly-traded global specialty chemicals and materials company. Dr. Johnson earned a BME (Bachelor of Mechanical Engineering) from Villanova University and holds a PhD and MS in metallurgical engineering and materials science from Carnegie-Mellon University. He also completed a three-year advanced business administration program through Arizona State University’s College of Business Administration. |
Joseph V. VumbaccoRetired Vice Chairman Health Management Associates, Inc. Joseph V. Vumbacco, age 65, has been a Director of IDEXX since February 2010. Mr. Vumbacco served as Chief Executive Officer of Health Management Associates, Inc., or HMA, from 2001 until June 2007, and as Vice Chairman of HMA from June 2007 until his retirement in December 2007. HMA is a premier operator of acute care hospitals in non-urban communities throughout the United States, and had over $4.1 billion in revenues during the last fiscal year prior to Mr. Vumbacco’s retirement. As the Chief Executive Officer of HMA, Mr. Vumbacco was responsible for all aspects of the business. Prior to becoming Chief Executive Officer, Mr. Vumbacco held several key positions at HMA from 1996, including Chief Operating Officer, Chief Administrative Officer, Executive Vice President, and President. Before joining HMA, Mr. Vumbacco had a nearly 15-year career with The Turner Corporation, a publicly-traded construction and real estate company, where he gained extensive operational and staff responsibilities, including as an Executive Vice President. Mr. Vumbacco also served as Senior Vice President and General Counsel at The F&M Schaefer Corporation, a publicly-traded brewing company, and prior to that was an attorney at the Wall Street firm of Mudge Rose Guthrie & Alexander where he specialized in corporate and securities law. Mr. Vumbacco holds an undergraduate degree from Bowdoin College, a law degree from Syracuse University College of Law, and he also completed the Finance Program for Senior Executives at the Harvard Business School. |
I. Organization
There shall be a Nominating and Governance Committee (the “Committee”) of the Board of Directors of IDEXX Laboratories, Inc. (the “Company”). The Committee shall consist of no less than three Directors designated by the Board of Directors, each of whom shall be “independent” under applicable law and NASDAQ rules, and shall be a non-employee director, as defined in Rule 16b-3 under the Securities Exchange Act of 1934, or any successor regulation. Members of the Committee shall be selected by the Board, upon the recommendation of the Committee, at the meeting of the Board immediately following the Company’s Annual Meeting of Stockholders for terms of one year, or until their successors are duly elected and qualified. The Board may remove members of the Nominating and Governance Committee from such committee, with or without cause. The Board shall elect the Chairman of the Committee.
II. Purpose
The purpose of the Committee is to advise the full Board on matters relating to corporate governance, including with respect to (1) Board organization, membership, function and performance, (2) nomination of persons for election as directors at any meeting of stockholders and nomination of persons to be elected by the Board to fill any vacancies on the Board, (3) Board committee structure and membership, (4) Corporate Governance Guidelines, and (5) significant stockholder relations issues.
III. Duties and Responsibilities
The duties and responsibilities of the Committee shall include the following, in addition to such other duties and responsibilities as may be delegated to the Committee from time to time by the Board.
- Review and recommend policies and principles for effective corporate governance, including the Company’s Corporate Governance Guidelines. The Committee shall review the Guidelines at least annually and recommend any proposed changes to the Board for approval.
- Advise the Board with respect to any proposed changes to the Company’s charter, by-laws and shareholder rights plan, if applicable.
- Identify, recruit, evaluate and nominate candidates to fill vacancies on the Board. The Board’s criteria for selecting directors are set forth in the Company’s Corporate Governance Guidelines. The Committee shall use the criteria and principles set forth in the Company’s Corporate Governance Guidelines to guide its process for selecting candidates to recommend to the Board for membership. The Committee shall be responsible for reviewing with the Board, on an annual basis, the requisite skills and criteria for new Board members as well as the composition of the Board as a whole. The Committee shall annually assess, for each Director or person nominated to become a Director, the specific experience, qualifications, attributes and skills that lead the Committee to conclude that such Director or nominee should serve as a Director, in light of the Company's business and structure. The Committee may adopt, and periodically review and revise as it deems appropriate, procedures regarding Director candidates proposed by stockholders.
- Extend invitations to join the Board to prospective Directors.
- Review, evaluate and administer resignation, retention and retirement policies applicable to the Board.
- Annually evaluate the independence of Directors and the satisfaction by Audit Committee members of any applicable criteria related to financial expertise, financial literacy and independence.
- Except where the Company is legally required by contract, by-law or otherwise to provide third parties with the right to nominate directors, recommend to the Board in advance of the Annual Meeting of Stockholders of the Company a proposed slate of Directors for submission to the Company’s stockholders. In making such recommendations, the Committee shall consider candidates proposed by stockholders. The Committee shall review and evaluate information available to it regarding candidates proposed by stockholders and shall apply the same criteria, and shall follow substantially the same process in considering them, as it does in considering other candidates.
- Review, evaluate and make recommendations to the Board regarding Board Committee charters, membership and chairmanships.
- Annually assess the performance of the Board, its Committees and each individual Director.
- Periodically access the Board's leadership structure, including whether the offices of Chairman of the Board and Chief Executive Officer should be separate and why the Board's leadership structure is appropriate given the specific characteristics or circumstances of the Company.
- Oversee and coordinate with management regarding Director education and orientation of new Directors.
- Annually nominate a Lead Director for approval by the Independent Directors (as defined by the Corporate Governance Guidelines) of the Board if the Chairman of the Board is not an Independent Director.
- Review and make recommendations regarding significant stockholder relations matters, including stockholder proposals that relate to corporate governance submitted for consideration at any Annual Meeting of Stockholders of the Company.
- Formulate and administer procedures for the communication by stockholders with the Board of Directors.
- Retain, at the Company’s expense, such independent counsel or other advisers, including recruiters, that it deems necessary. Such independent advisors may be the regular advisors to the Company.
- Form and delegate authority to sub-committees or individual members of the Committee.
- Annually conduct a review of this Charter and recommend any proposed changes to the Board.
IV. Meetings
The Committee shall meet at least three times annually and at such other times as shall be determined by the Chairman of the Committee. The Committee shall report the results of its meetings regularly to the Board. The Committee is governed by the same rules regarding meetings as are applicable to the Board.

![]() | Rebecca M. Henderson, PhDSenator John Heinz Professor of Environmental Management Harvard Business School Rebecca M. Henderson, age 51, has been a Director of IDEXX since July 2003. Dr. Henderson has extensive experience in corporate strategy, with a focus on high-technology business. She has worked with numerous Fortune 500 companies on growth strategies related to innovation. In July 2009 Dr. Henderson joined Harvard Business School as the Senator John Heinz Professor of Environmental Management where she specializes in strategy and organizational change. From 1998 to 2009, Dr. Henderson served as the Eastman Kodak Professor of Management at the Sloan School of the Massachusetts Institute of Technology. Dr. Henderson also has board oversight and corporate governance experience as a director since July 2009 of Amgen Inc., a publicly-traded human therapeutics company in the biotechnology industry, and as a director of several private company and non-profit organization boards. Dr. Henderson also has been a research fellow at the National Bureau of Economic Research since 1995, and sits on the editorial boards of Management Science, Research Policy, The Economics of Innovation and New Technology, and the Strategy Management Journal. Dr. Henderson holds an undergraduate degree from the Massachusetts Institute of Technology and a PhD in business economics from Harvard University. |
![]() | William T. EndRetired Executive Chairman of the Board Cornerstone Brands, Inc. William T. End, age 64, has been a Director of IDEXX since July 2000. Mr. End was Chairman and Chief Executive Officer of Cornerstone Brands, Inc., a privately-held catalog retailer, from 1995 to 2001, and Executive Chairman of that company from 2001 until his retirement in 2002. In these executive roles Mr. End was responsible for all corporate functions as well as Board function and activity. Prior to joining Cornerstone Brands, Mr. End held various positions at Land’s End, Inc. from 1991 to 1995, including President and Chief Executive Officer. From 1975 to 1991, Mr. End held various positions at L.L. Bean, Inc., a privately-held catalog retailer, including Executive Vice President and Chief Marketing Officer. Mr. End has significant executive experience with a particular focus on marketing and product development. Mr. End was a director and chairman of Eddie Bauer Holdings, Inc., a catalog retailer, from 2005 to 2010, a director of New England Business Services, Inc., a business to business direct marketing company, from 2000 to 2003, Hannaford Bros. Co., a supermarket and grocery retailer, from 1995 to 2000, and Land’s End, Inc., a catalog retailer, from 1990 to 1995. He also has been a director of several non-public companies. In these capacities, Mr. End has developed significant experience with board function and corporate governance. Mr. End received a BSBA from Boston College and earned an MBA from Harvard Business School. |
![]() | Robert J. MurrayRetired Chairman and Chief Executive Officer New England Business Service Robert J. Murray, age 70, has been a Director of IDEXX since February 2005. Mr. Murray served as Chairman of the Board and Chief Executive Officer of New England Business Service, Inc., or NEBS, from 1995 until his retirement in 2004. NEBS was a publicly-traded business to business direct marketing company and had over $500 million in sales during the last fiscal year prior to Mr. Murray’s retirement. As the chief executive officer of NEBS, Mr. Murray was responsible for all aspects of the business. Mr. Murray held various executive positions at The Gillette Company from 1961 to 1995, including Executive Vice President, North Atlantic Group from 1991 to 1995, and Chairman of the Board of Management of Braun AG, a subsidiary of Gillette headquartered in Germany, from 1985 to 1990. In these positions, Mr. Murray developed substantial experience in international business operations and led all aspects of the business for these divisions. Mr. Murray has served as a director for the following public companies since the years indicated: The Hanover Insurance Group, Inc., a property and casualty insurance company (since 1996); LoJack Corporation, an automobile security system manufacturer (since 1992); Tupperware Brands Corporation, a consumer-direct seller of personal and household products (since 2004); and Delhaize Group, an international food retailer based in Belgium (since 2001). Mr. Murray’s background as a chief executive as well as a leader of a major business unit of a large multi-national corporation, and as a director of several public companies, has provided him with extensive management skills and experience in board function and corporate governance. Mr. Murray received a BS and BA from Boston College and an MBA from Northeastern University and he completed Harvard Business School’s Advanced Management Program. |
I. Organization
There shall be a Compensation Committee of the Board of Directors of IDEXX Laboratories, Inc. (the “Company”). The Committee shall consist of at least three directors designated by the Board of Directors, each of whom shall be (a) “independent” under the Company’s Corporate Governance Guidelines and applicable laws, regulations and listing standards, (b) a non-employee director, as defined in Rule 16b-3 under the Securities Exchange Act of 1934, or any successor regulation, and (c) an “outside director” within the meaning of section 162(m) of the Internal Revenue Code. Members of the Committee shall be selected by the Board, upon recommendation of the Nominating and Governance Committee of the Board, immediately following the Company’s Annual Meeting of Stockholders. The Board may remove members of the Compensation Committee from such committee, with or without cause. Members of the Committee shall serve for terms of one year, or until their successors are duly elected and qualified. The Board shall elect the Chairman of the Committee.
II. Purpose
The purpose of the Committee is to oversee the discharge the responsibilities of the Board relating to compensation of the Company’s executive officers and directors, evaluate the performance of the Chief Executive Officer, oversee succession planning for the Chief Executive Officer, and oversee the management of the Company’s incentive compensation, equity compensation and benefit plans.
III. Duties and Responsibilities
The duties and responsibilities of the Committee shall include the following, in addition to such other duties and responsibilities as may be delegated to the Committee from time to time by the Board.
- Determine the Company’s philosophy relating to the compensation of executive officers and annually review that philosophy.
- Annually evaluate the Chief Executive Officer’s performance against annual financial and non-financial goals and objectives established by the Board of Directors, and determine the Chief Executive Officer’s salary, bonus, equity compensation and other compensation and benefits based on this evaluation. The Compensation Committee or the independent directors, as the case may be, shall meet without the presence of executive officers when approving or deliberating on Chief Executive Officer compensation.
- Review and make recommendations to the Board with respect to the adoption, amendment and termination of the Company’s incentive compensation, equity compensation, retirement and other benefit plans, oversee their administration and discharge any duties imposed on the Committee by any of those plans. The Committee shall determine the authority of the Company’s Employee Plans Administrative Committee and shall designate the members of such committee.
- Exercise all rights, authority and function of the Board under the Company's equity incentive plans, including without limitation the authority to interpret the terms thereof and grant awards thereunder, except as otherwise provided by the Board or the terms of such plans.
- Assess the competitiveness and appropriateness of, approve, and authorize the salaries, incentive compensation, equity compensation, terms of employment, retirement or severance benefits, and perquisites of the executive officers of the Company. The Chief Executive Officer shall recommend to the Committee annual compensation for the rest of the executive officers and the Committee may make such changes to such recommendations as it deems appropriate.
- Review and authorize the eligibility criteria and award guidelines for compensation programs in which non-executive officer management employees participate, including incentive compensation and equity awards. The Committee may delegate to the Chief Executive Officer the authority to allocate such awards among employees other than executive officers, subject to such parameters as the Committee or the Board shall determine and to the limitations set forth in the applicable plans pursuant to which such awards are to be granted.
- Annually review succession plans for the Chief Executive Officer.
- Annually review compliance by executive officers and directors with the Company’s stock ownership and retention guidelines.
- Exercise the sole authority to retain and terminate any compensation consultant used to provide advice with respect to the compensation of executive officers, and approve the fees of such consultant. The Committee may also retain such independent counsel or other advisers that it deems necessary. Independent advisors other than compensation consultants retained by the Committee may be the regular advisors to the Company. The Company shall provide appropriate funding, as determined by the Committee, for payment of the fees of any such compensation consultants, independent counsel or other advisors.
- Review and discuss annually with management the Company’s “Compensation Discussion and Analysis” required by Item 402(b) of Regulation S-K (the “CD&A”). The Compensation Committee shall consider annually whether it will recommend to the Board that the CD&A be included in the Company’s Annual Report on Form 10-K and proxy statement.
- Prepare the annual Compensation Committee Report required by Item 407(e)(5) of Regulation S-K.
- Review and make recommendations to the Board regarding compensation of directors.
- Form and delegate authority to sub-committees or individual members of the Committee.
- Annually conduct a review of this Charter and recommend any proposed changes to the Board.
IV. Meetings
The Committee shall meet during the first quarter of each year to evaluate the Chief Executive Officer’s performance during the preceding year and to approve executive officer compensation, and shall meet at such other times as shall be determined by the Chairman of the Committee. The Committee shall report the results of its meetings regularly to the Board. The Committee is governed by the same rules regarding meetings as are applicable to the Board.


![]() | Robert J. MurrayRetired Chairman and Chief Executive Officer New England Business Service Robert J. Murray, age 70, has been a Director of IDEXX since February 2005. Mr. Murray served as Chairman of the Board and Chief Executive Officer of New England Business Service, Inc., or NEBS, from 1995 until his retirement in 2004. NEBS was a publicly-traded business to business direct marketing company and had over $500 million in sales during the last fiscal year prior to Mr. Murray’s retirement. As the chief executive officer of NEBS, Mr. Murray was responsible for all aspects of the business. Mr. Murray held various executive positions at The Gillette Company from 1961 to 1995, including Executive Vice President, North Atlantic Group from 1991 to 1995, and Chairman of the Board of Management of Braun AG, a subsidiary of Gillette headquartered in Germany, from 1985 to 1990. In these positions, Mr. Murray developed substantial experience in international business operations and led all aspects of the business for these divisions. Mr. Murray has served as a director for the following public companies since the years indicated: The Hanover Insurance Group, Inc., a property and casualty insurance company (since 1996); LoJack Corporation, an automobile security system manufacturer (since 1992); Tupperware Brands Corporation, a consumer-direct seller of personal and household products (since 2004); and Delhaize Group, an international food retailer based in Belgium (since 2001). Mr. Murray’s background as a chief executive as well as a leader of a major business unit of a large multi-national corporation, and as a director of several public companies, has provided him with extensive management skills and experience in board function and corporate governance. Mr. Murray received a BS and BA from Boston College and an MBA from Northeastern University and he completed Harvard Business School’s Advanced Management Program. |
Thomas CraigPartner and co-founder Monitor Company Group, L.P. Thomas Craig, age 56, has been a Director of IDEXX since December 1999. Mr. Craig has extensive experience in management consulting and corporate growth strategy. In 1983, Mr. Craig co-founded Monitor Company Group, L.P., a global management consulting firm committed to helping clients improve their competitiveness and providing services in strategy consulting, capability building, and capital services. Mr. Craig has broad international and industry experience. He has worked in over 70 countries on six continents and has led over 400 projects over the past 32 years, mostly for Fortune 500 companies or their international equivalents, or at the highest levels of government. Mr. Craig continues to be a partner at Monitor and is responsible for development of various emerging narkets, as well as serving clients in North America. He is active in various executive education programs and leadership development initiatives. Mr. Craig received an AB from Princeton University and holds an MBA from Harvard Business School. |
![]() | William T. EndRetired Executive Chairman of the Board Cornerstone Brands, Inc. William T. End, age 64, has been a Director of IDEXX since July 2000. Mr. End was Chairman and Chief Executive Officer of Cornerstone Brands, Inc., a privately-held catalog retailer, from 1995 to 2001, and Executive Chairman of that company from 2001 until his retirement in 2002. In these executive roles Mr. End was responsible for all corporate functions as well as Board function and activity. Prior to joining Cornerstone Brands, Mr. End held various positions at Land’s End, Inc. from 1991 to 1995, including President and Chief Executive Officer. From 1975 to 1991, Mr. End held various positions at L.L. Bean, Inc., a privately-held catalog retailer, including Executive Vice President and Chief Marketing Officer. Mr. End has significant executive experience with a particular focus on marketing and product development. Mr. End was a director and chairman of Eddie Bauer Holdings, Inc., a catalog retailer, from 2005 to 2010, a director of New England Business Services, Inc., a business to business direct marketing company, from 2000 to 2003, Hannaford Bros. Co., a supermarket and grocery retailer, from 1995 to 2000, and Land’s End, Inc., a catalog retailer, from 1990 to 1995. He also has been a director of several non-public companies. In these capacities, Mr. End has developed significant experience with board function and corporate governance. Mr. End received a BSBA from Boston College and earned an MBA from Harvard Business School. |
![]() | Brian P. McKeonExecutive Vice President and Chief Financial Officer Iron Mountain Incorporated Brian P. McKeon, age 49, has been a Director of IDEXX since July 2003. As a CPA with nearly 20 years of experience as a finance executive, Mr. McKeon has significant background in finance, financial reporting, financial controls, mergers and acquisitions, and strategic planning, including as Executive Vice President and Chief Financial Officer for Iron Mountain Incorporated since April 2007. Iron Mountain is a publicly-traded provider of information protection and storage services worldwide with over $3 billion in revenues during 2009. Mr. McKeon was also Executive Vice President and Chief Financial Officer of The Timberland Company from March 2000 to April 2007. Timberland is a publicly-traded provider of premium outdoor footwear, apparel and accessories that had over $1.5 billion in revenues in 2006, the last full fiscal year of Mr. McKeon’s tenure. From 1991 to 2000, Mr. McKeon held several finance and strategic planning positions with PepsiCo Inc., serving most recently as Vice President, Finance at Pepsi-Cola, North America. Prior to joining PepsiCo, Mr. McKeon worked as a strategy consultant with the Alliance Consulting group and as an auditor with Coopers & Lybrand. Mr. McKeon earned a BS from the University of Connecticut and received an MBA from Harvard University. |
I. Organization
There shall be a Finance Committee (the “Committee”) of the Board of Directors of IDEXX Laboratories, Inc. (the “Company”). The Committee shall consist of at least three directors designated by the Board of Directors, each of whom shall be “independent” under applicable law and stock exchange regulations, and shall be a non-employee director, as defined in Rule 16b-3 under the Securities Exchange Act of 1934, or any successor regulation. Members of the Committee shall be selected by the Board at the meeting of the Board immediately following the Company’s Annual Meeting of Stockholders for terms of one year, or until their successors are duly elected and qualified. The Board of Directors may remove members of the Committee from such committee, with or without cause. The Board shall elect the Chairman of the Committee.
II. Purpose
The purpose of the Committee is to advise the full Board on matters relating to capital structure and strategies, financing strategies, major financial commitments, acquisitions and divestitures, financial risk management, and investing and banking activities.
III. Duties and Responsibilities
The duties and responsibilities of the Committee shall include the following, in addition to such other duties and responsibilities as may be delegated to the Committee from time to time by the Board.
- Review and make recommendations to the Board regarding significant financing activities, including the issuance of equity or debt.
- Monitor the Company’s liquidity and financial condition.
- Oversee the Company’s investment policies and practices.
- Review and approve stock repurchase activities, including changes in parameters of repurchase programs such as number of shares authorized for repurchase and maximum repurchase prices.
- Oversee the Company’s financial risk management activities, including foreign currency hedging activities and transactions involving derivative instruments.
- Review and make recommendations to the Board regarding dividend policy.
- Review and approve proposed acquisitions and divestitures requiring Board approval and having values up to $20 million.
- Review and approve non-budgeted expenditures requiring Board approval.
- Annually conduct a review of this Charter and recommend any proposed changes to the Board.
- Retain, at the Company’s expense, such independent counsel or other advisers as it deems necessary.
- Form and delegate authority to sub-committees or individual members of the Committee.
IV. Meetings
The Committee shall meet at least once annually and at such other times as shall be determined by the Chairman of the Committee. The Committee is governed by the same rules regarding meetings as are applicable to the Board.

![]() | Barry C. Johnson, PhDFormer Dean, College of Engineering Villanova University Barry C. Johnson, age 68, has been a Director of IDEXX since March 2006. Dr. Johnson has substantial experience in science and technology and in research and product development. Dr. Johnson served as Dean, College of Engineering, Villanova University, from August 2002 until his retirement in May 2006. From July 2000 to April 2002, he served as Senior Vice President and Chief Technology Officer of Honeywell International, Inc., a worldwide diversified technology and manufacturing company with sales in 2001 exceeding $23 billion. As Chief Technology Officer, Dr. Johnson was responsible for setting the strategic direction and prioritization of Honeywell’s research and development organization, which was supported by a global network of more than 15,000 engineers, scientists and researchers. Prior to Honeywell, Dr. Johnson served in several roles beginning in 1976 at Motorola, Inc., a global leader in providing integrated communications solutions, including Corporate Vice President and Chief Technology Officer for that company’s Semiconductor Product Sector. Dr. Johnson also has board oversight and corporate governance experience from his service as a director since September 2005 of Rockwell Automation, Inc., a publicly-traded global automation solutions company, and as a director since August 2003 of Cytec Industries, Inc., a publicly-traded global specialty chemicals and materials company. Dr. Johnson earned a BME (Bachelor of Mechanical Engineering) from Villanova University and holds a PhD and MS in metallurgical engineering and materials science from Carnegie-Mellon University. He also completed a three-year advanced business administration program through Arizona State University’s College of Business Administration. |
![]() | Rebecca M. Henderson, PhDSenator John Heinz Professor of Environmental Management Harvard Business School Rebecca M. Henderson, age 51, has been a Director of IDEXX since July 2003. Dr. Henderson has extensive experience in corporate strategy, with a focus on high-technology business. She has worked with numerous Fortune 500 companies on growth strategies related to innovation. In July 2009 Dr. Henderson joined Harvard Business School as the Senator John Heinz Professor of Environmental Management where she specializes in strategy and organizational change. From 1998 to 2009, Dr. Henderson served as the Eastman Kodak Professor of Management at the Sloan School of the Massachusetts Institute of Technology. Dr. Henderson also has board oversight and corporate governance experience as a director since July 2009 of Amgen Inc., a publicly-traded human therapeutics company in the biotechnology industry, and as a director of several private company and non-profit organization boards. Dr. Henderson also has been a research fellow at the National Bureau of Economic Research since 1995, and sits on the editorial boards of Management Science, Research Policy, The Economics of Innovation and New Technology, and the Strategy Management Journal. Dr. Henderson holds an undergraduate degree from the Massachusetts Institute of Technology and a PhD in business economics from Harvard University. |
Joseph V. VumbaccoRetired Vice Chairman Health Management Associates, Inc. Joseph V. Vumbacco, age 65, has been a Director of IDEXX since February 2010. Mr. Vumbacco served as Chief Executive Officer of Health Management Associates, Inc., or HMA, from 2001 until June 2007, and as Vice Chairman of HMA from June 2007 until his retirement in December 2007. HMA is a premier operator of acute care hospitals in non-urban communities throughout the United States, and had over $4.1 billion in revenues during the last fiscal year prior to Mr. Vumbacco’s retirement. As the Chief Executive Officer of HMA, Mr. Vumbacco was responsible for all aspects of the business. Prior to becoming Chief Executive Officer, Mr. Vumbacco held several key positions at HMA from 1996, including Chief Operating Officer, Chief Administrative Officer, Executive Vice President, and President. Before joining HMA, Mr. Vumbacco had a nearly 15-year career with The Turner Corporation, a publicly-traded construction and real estate company, where he gained extensive operational and staff responsibilities, including as an Executive Vice President. Mr. Vumbacco also served as Senior Vice President and General Counsel at The F&M Schaefer Corporation, a publicly-traded brewing company, and prior to that was an attorney at the Wall Street firm of Mudge Rose Guthrie & Alexander where he specialized in corporate and securities law. Mr. Vumbacco holds an undergraduate degree from Bowdoin College, a law degree from Syracuse University College of Law, and he also completed the Finance Program for Senior Executives at the Harvard Business School. |
Executive Officers
![]()
IDEXX’s executive officers are appointed by the Board of Directors to carry out the Board’s policies and manage the daily affairs of the Company.
Chairman, President and Chief Executive Officer
![]() | Jonathan W. AyersChairman, President and Chief Executive Officer Jonathan W. Ayers has served as Chairman, President and CEO of IDEXX Laboratories, Inc., since January 2002. Before joining IDEXX, from 1999 to 2001, Mr. Ayers served as President of Carrier Corporation, the then-largest business unit of United Technologies Corporation, and from 1997 to 1999 he was President of Carrier’s Asia Pacific Operations. From 1995 to 1997, Mr. Ayers was Vice President, Strategic Planning at United Technologies. Before joining United Technologies, from 1986 to 1995, Mr. Ayers held various positions at Morgan Stanley & Co. in mergers and acquisitions and corporate finance. Prior to Morgan Stanley, Mr. Ayers was a strategy consultant for Bain & Company from 1983 to 1986 and was in the field sales organization of IBM’s Data Processing Division from 1978 to 1981. Mr. Ayers holds a bachelor’s degree in molecular biophysics and biochemistry from Yale University, and a master’s in business administration from Harvard University. |
Corporate Vice President and Chief Scientific Officer
![]() | William E. Brown, III, PhDCorporate Vice President and Chief Scientific Officer Dr. Brown became Chief Scientific Officer, overseeing all Research and Development activities in the Company, in March 2010. He first joined IDEXX as Corporate Vice President, Instrument Research and Development and Manufacturing, in December 2008. Before joining the Company, Dr. Brown was a Corporate Officer and Divisional Vice President of R&D, Assays and Instrument Systems for the Diagnostic Division of Abbott Laboratories, Inc. Most recently he was responsible for R&D portfolio development, new product launches, and basic research for immunoassay, clinical chemistry and instrument systems. In his twenty-five years with Abbott, Dr. Brown held various senior leadership positions, developing in-depth expertise in product development, manufacturing, and quality assurance for both life science and instrument systems. Dr. Brown earned his bachelor’s degree in chemistry education from Indiana University of Pennsylvania and his doctorate in medicinal chemistry from the University of Pittsburgh, School of Pharmacy. |
Corporate Vice President, General Counsel and Secretary
![]() | Conan R. DeadyCorporate Vice President, General Counsel and Secretary Mr. Deady has been Corporate Vice President and General Counsel of the Company since August 1999, and has been leading the Company’s business development activities since April 2005 and its regulatory functions since October 2008. Mr. Deady was Deputy General Counsel of the Company from June 1997. Before joining the Company in June 1997, Mr. Deady was Deputy General Counsel of Thermo Electron Corporation (now Thermo Fisher Scientific, Inc.), a provider of analytical and laboratory products and services. Mr. Deady was previously affiliated with Hale and Dorr, a Boston law firm. Mr. Deady received his BA from Amherst College and his JD from the University of Virginia. |
Corporate Vice President, Companion Animal Group
![]() | George J. FennellCorporate Vice President, Companion Animal Group Mr. Fennell joined IDEXX in June 2011 as a Corporate Vice President of the Company, and leads the Companion Animal Group Customer Facing Organization in North America. Mr. Fennell came to IDEXX from Pfizer Animal Health where he began as head of marketing for the companion animal business for two years, subsequently served five years as vice president of the U.S. Companion Animal Division, and since January 2011, was Vice President, Pfizer Animal Genetics, Diagnostics and Aquaculture. Before his tenure at Pfizer, he held a series of sales, marketing and operational roles in the crop sciences business for American Cyanamid and BASF. Mr. Fennell earned his bachelor’s degree in economics and agricultural business from the University of Delaware. |
Corporate Vice President, Worldwide Operations
![]() | Dan MeyaardCorporate Vice President, Worldwide Operations Mr. Meyaard became a Corporate Vice President of the Company in September 2009, and oversees Worldwide Operations. Before joining IDEXX, Mr. Meyaard held various leadership positions over the course of 29 years at Bayer/Siemens, the world’s largest clinical diagnostics company. Most recently Mr. Meyaard was Vice President of Global Instrument Manufacturing for Siemens Medical Solutions Diagnostics. Prior to that, he served as Vice President for a number of operations, including OEM Reagents and Consumables, Global OEM Management, and Global Strategic Procurement. Mr. Meyaard earned his bachelor’s degree in chemistry from Calvin College in Grand Rapids, Michigan. |
Corporate Vice President, International
![]() | Ali Naqui, PhDCorporate Vice President, International Dr. Naqui has been Corporate Vice President of the Company since January 2006 and has overseen the Company’s international commercial operations since December 2007 and its Asia Pacific and Latin American operations since January 2006. Dr. Naqui led the Company’s Water and Dairy businesses from January 2000 to December 2007. He was General Manager, Water from September 1997 to January 2000, and Director of Research and Development from February 1993 to September 1997. Dr. Naqui joined the Company in 1993 as a result of its acquisition of Environetics, where he was the Director of Research and Development. Prior to joining Environetics, he was a Research and Development manager with Becton, Dickinson and Company. Dr. Naqui received his PhD from the Department of Chemical Enzymology at Moscow State University. He received his post-doctoral training at the Department of Biochemistry and Biophysics at the University of Pennsylvania. |
Corporate Vice President, Rapid Assay and Digital
![]() | James PolewaczykCorporate Vice President, Rapid Assay and Digital Mr. Polewaczyk joined IDEXX as Corporate Vice President of the Company in February 2007 and oversees the Company’s Rapid Assay and Digital businesses. Mr. Polewaczyk came to IDEXX from Philips Medical Systems, a subsidiary of Royal Philips Electronics, The Netherlands, where he was General Manager, Medical Consumables and Sensors Business. Prior to Philips, Mr. Polewaczyk spent 15 years at Hewlett-Packard, holding a variety of senior marketing and product development positions in their Medical Products Group. Mr. Polewaczyk holds a bachelor’s degree in electrical engineering from Worcester Polytechnic Institute and a master’s degree in business from Boston University. |
Corporate Vice President, IDEXX Reference Laboratories
![]() | Johnny D. Powers, PhDCorporate Vice President, IDEXX Reference Laboratories Dr. Powers joined IDEXX as Corporate Vice President in February 2009 to oversee the Company’s worldwide reference laboratories business. Prior to joining the Company, Dr. Powers was Vice President responsible for the Cancer Diagnostics business of Becton Dickinson and Company from 2007 to 2008. Dr. Powers came to Becton Dickinson as a result of its acquisition in 2007 of TriPath Imaging Inc., where he held various positions from 2001 to 2007, most recently serving as President, TriPath Oncology business unit. Prior to joining Tripath, Dr. Powers was employed for five years by Ventana Medical Systems, most recently as Vice President and General Manager of Manufacturing Operations. Before that, he spent seven years in various technical manufacturing roles at Organon Teknika Corporation. Dr. Powers holds a PhD in biochemical engineering from North Carolina State University, an MBA from the Duke University Fuqua School of Business, an MS in chemical engineering from Clemson University, and a BA in chemistry from Wake Forest University. |
Corporate Vice President, Chief Financial Officer and Treasurer
![]() | Merilee RainesCorporate Vice President, Chief Financial Officer and Treasurer Ms. Raines became Chief Financial Officer of the Company in October 2003. Ms. Raines was Corporate Vice President of Finance of the Company starting in May 1995, Vice President and Treasurer of Finance from March 1995 to May 1995, Director of Finance from 1988 to March 1995, and Controller from 1985 to 1988. Ms. Raines earned a bachelor’s degree in mathematics from Bowdoin College and an MBA from the University of Chicago. |
Corporate Vice President, Human Resources
![]() | Giovani TwiggeCorporate Vice President, Human Resources Mr. Twigge became a Corporate Vice President of the Company in August 2010, and oversees worldwide Human Resources. Before joining IDEXX, Mr. Twigge held various Human Resources leadership positions over the course of 11 years at Abbott Laboratories, a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products, and diagnostics. Most recently Mr. Twigge was Divisional Vice President, HR, for Abbott Diagnostics. Prior to that, he served as Divisional Vice President, HR, for Abbott Nutrition International and as Regional HR Director for a number of international operations including those in Europe, Latin America/Canada and the Middle East. Mr. Twigge earned his B. Commerce (Honors) degree in personnel management from the University of Pretoria, South Africa. |
Corporate Vice President, Instrument Diagnostics
![]() | Michael Williams, PhDCorporate Vice President, Instrument Diagnostics Dr. Williams became a Corporate Vice President of the Company in September 2006 and has been General Manager of the Companion Animal Instrument and Consumables business since 2004. Dr. Williams has also supervised the OPTI Medical Systems business since its acquisition in February 2007. Dr. Williams joined IDEXX in January of 2003 as Vice President and General Manager of the Company’s chemistry instruments and consumables business. Prior to joining IDEXX, Dr. Williams worked as a Senior Research Associate at the Scripps Research Institute, Department of Vascular Biology, for several years and then joined McKinsey & Company for seven years as a healthcare strategy consultant. Dr. Williams received his bachelor’s degree in biochemistry from the University of Bristol, United Kingdom, and his doctorate in biochemistry from Wadham College, University of Oxford, United Kingdom. |



















